Nomura Holdings’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-27,241
Closed -$814K 2126
2025
Q4
$1.04M Buy
+27,241
New +$886K ﹤0.01% 1328
2020
Q4
Sell
-48,893
Closed -$906K 1655
2020
Q3
$906K Sell
48,893
-68,107
-58% -$1.32M ﹤0.01% 848
2020
Q2
$2.38M Buy
+117,000
New +$1.86M 0.01% 528
2020
Q1
Sell
-9,503
Closed -$135K 1219
2019
Q4
$135K Sell
9,503
-2,497
-21% -$31.9K ﹤0.01% 1023
2019
Q3
$136K Sell
12,000
-500
-4% -$8.26K ﹤0.01% 1108
2019
Q2
$257K Buy
+12,500
New +$247K ﹤0.01% 1020

Other funds holding TVTX

Nomura Holdings's TVTX Position: Q1 2026 in Review

Nomura Holdings sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 27,241 shares — an estimated $814K sold.

Nomura Holdings first reported a position in TVTX in Q2 2019 and held it in 6 quarters. The position peaked at $2.38M in Q2 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Nomura Holdings reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nomura Holdings sold 27,241 Travere Therapeutics shares in Q1 2026, an estimated $814K.
  • Nomura Holdings first reported a position in Travere Therapeutics in Q2 2019 and held it in 6 quarters.
  • Nomura Holdings's Travere Therapeutics position peaked at $2.38M in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.